[TimAlerts] VBLT :"We look forward to this opportunity at ECC 2015 to present complete results from this important Phase 2 trial of VB-111 in rGBM," stated Professor Dror Harats, CEO of VBL Therapeutics. "The presentation will include response rates in patients, as well as updated results on overall survival and response rate. We are excited to move forward with development of this first-in-class biologic agent and continue recruiting to our recently launched pivotal Phase 3 study in rGBM."... (results